(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB APPROVAL							
	OMB Number:	3235-028						
Estimated average burden								
	hours per response	0 4						

longer subject to Section 16. Form 4 or Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of JAMES N		2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_Director 10% Owner							
					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2008						X	X Officer (give title below) Other (specify below) CEO & Board Chairman					
					4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH SAN FRANCISCO, CA 94080																	
(Ci	ty)	(State)	(Zip)				Tal	ole I - No	n-Deriv	ative Securities	Acquired,	Disposed of	, or Benefic	ially Owned			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year		ear) Ex			Coc (Ins	3. Transaction Code (Instr. 8)		Securities Acqui or Disposed of str. 3, 4 and 5)	(D) Owned Following Transaction(s)			C	wnership orm:	Beneficial			
				(M	lonth	onth/Day/Year)		Code	V An	(A) or	(Instr	(Instr. 3 and 4) Direct (D) or Indirect (I) (Instr. 4)		Ownership Instr. 4)			
			Table					th cu cquired,	is form arrently Dispose	who respond are not requiversalid OMB co ed of, or Benefic vertible securiti	red to respontrol num	ond unles ber.			1 SEC 1	474 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) of ntive	Execution Date, if T	Code	Fransaction Code Se Instr. 8) Ac or		5. Number of		Exercisation Date //Day/Ye		7. Title and of Underly Securities (Instr. 3 and	ing		f 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivativ Security: Direct (I or Indire	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercise	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (Right to Buy)	\$ 26.45	01/31/2008		A		165,000		02/01/	2008 <sup>(1</sup>	01/31/2018	Commor Stock	165,000	\$ 0	165,000	D		

# **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOWER JAMES M RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO & Board Chairman				

# **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	02/01/2008
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from 1/01/08.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.